Biomea Fusion (BMEA) Cash from Financing Activities (2020 - 2025)
Biomea Fusion (BMEA) posted Cash from Financing Activities of $23.1 million for Q4 2025, up 1074.39% sequentially from $2.0 million in Q3 2025, and up 5496.13% YoY from $413000.0 in Q4 2024.
Biomea Fusion (BMEA) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Biomea Fusion has reported Cash from Financing Activities for 6 years, with the latest figure at $23.1 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 5496.13% year-over-year to $23.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.9 million (up 3970.98% YoY) and the FY2025 annual result came in at $67.9 million, up 3970.98% from the prior year.
- Cash from Financing Activities advanced to $23.1 million in Q4 2025 per BMEA's latest filing, from $2.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $162.8 million in Q2 2023 and troughed at -$3000.0 in Q1 2021.
- A 5-year average of $20.4 million and a median of $413000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2021 and 2023: Cash from Financing Activities plunged 106.0% in 2021, then jumped 51106.6% in 2023.
- Over 5 years, Cash from Financing Activities stood at $246000.0 in 2021, then soared by 99.19% to $490000.0 in 2022, then rose by 26.94% to $622000.0 in 2023, then plunged by 33.6% to $413000.0 in 2024, then jumped by 5496.13% to $23.1 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $23.1 million, $2.0 million, and $39.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.11 Mn |
| Dec 31, 2025 | 23.11 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 39.57 Mn |
| Jun 30, 2025 | 39.57 Mn |
| Mar 31, 2025 | 3.25 Mn |
| Mar 31, 2025 | 3.25 Mn |
| Dec 31, 2024 | 413,000.00 |
| Dec 31, 2024 | 413,000.00 |
| Sep 30, 2024 | 69,000.00 |
| Sep 30, 2024 | 69,000.00 |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 116,000.00 |
| Mar 31, 2024 | 116,000.00 |
| Dec 31, 2023 | 622,000.00 |
| Dec 31, 2023 | 622,000.00 |
| Sep 30, 2023 | 138,000.00 |
| Sep 30, 2023 | 138,000.00 |